Norepinephrine Bitartrate in Dextrose

Product NDC
25021-325
11-digit product format
250210325
Labeler code
25021
Product ID
25021-325_31e01df0-0db5-49f8-9813-740020665889
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Norepinephrine Bitartrate
Dosage form
INJECTION, SOLUTION
Route
INTRAVENOUS
Labeler
Sagent Pharmaceuticals
Application
ANDA219692
Marketing category
ANDA
Marketing start
2026-11-15
Substance
NOREPINEPHRINE BITARTRATE
Active strength
16 ug/mL
Pharmacologic classes
Catecholamine [EPC], Catecholamines [CS]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A219692-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSENOREPINEPHRINE BITARTRATEEQ 4MG BASE/250ML (EQ 16MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11
A219692-002NOREPINEPHRINE BITARTRATE IN 5% DEXTROSENOREPINEPHRINE BITARTRATEEQ 8MG BASE/250ML (EQ 32MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A219692-001AP
A219692-002AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A219692-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 4MG BASE/250ML (EQ 16MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11d4dbc9d85df4…
2026-11-14 07:37:172026-10A219692-002NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 8MG BASE/250ML (EQ 32MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11d4dbc9d85df4…
2026-10-15 13:18:302026-09A219692-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 4MG BASE/250ML (EQ 16MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11c2088c7a36db…
2026-10-15 13:18:302026-09A219692-002NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 8MG BASE/250ML (EQ 32MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11c2088c7a36db…
2026-09-14 22:38:342026-08A219692-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 4MG BASE/250ML (EQ 16MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-1184e616aacf4f…
2026-09-14 22:38:342026-08A219692-002NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 8MG BASE/250ML (EQ 32MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-1184e616aacf4f…
2026-08-18 06:07:402026-07A219692-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 4MG BASE/250ML (EQ 16MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11caaa826d4ba7…
2026-08-18 06:07:402026-07A219692-002NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 8MG BASE/250ML (EQ 32MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A219692-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 4MG BASE/250ML (EQ 16MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11011fe1cb6892…
2026-02-19 14:30 UTC2026-02A219692-002NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 8MG BASE/250ML (EQ 32MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A219692-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 4MG BASE/250ML (EQ 16MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-1131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A219692-002NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 8MG BASE/250ML (EQ 32MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-1131067a03dcf5…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219692-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 4MG BASE/250ML (EQ 16MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219692-002NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEEQ 8MG BASE/250ML (EQ 32MCG BASE/ML)SOLUTION / INTRAVENOUSAP2025-08-11a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A219692-001AP1d4dbc9d85df4…
2026-11-14 07:37:172026-10A219692-002AP1d4dbc9d85df4…
2026-10-15 13:18:302026-09A219692-001AP1c2088c7a36db…
2026-10-15 13:18:302026-09A219692-002AP1c2088c7a36db…
2026-09-14 22:38:342026-08A219692-001AP184e616aacf4f…
2026-09-14 22:38:342026-08A219692-002AP184e616aacf4f…
2026-08-18 06:07:402026-07A219692-001AP1caaa826d4ba7…
2026-08-18 06:07:402026-07A219692-002AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A219692-001AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A219692-002AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A219692-001AP131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A219692-002AP131067a03dcf5…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219692-001AP1a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219692-002AP1a50c72e98297…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startSampleExclude flagStatus
25021-325-842502103258410 BAG in 1 CARTON (25021-325-84) / 250 mL in 1 BAG10 bag2026-11-15NoNoHistorical